An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs

Janelle Applequist; Jennifer Gerard Ball

doi:10.1370/afm.2220

Published eLetters

If you would like to comment on this article, click on Submit a Response to This article, below. We welcome your input.

Submit a Response to This Article

Compose eLetter

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

What code is in the image? *

Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

A Screenful of Sugar?
Jon Schommer

Published on: 24 May 2018
Time for Congress to act
Dominick L. Frosch

Published on: 16 May 2018

Published on: (24 May 2018)
Page navigation anchor for A Screenful of Sugar?
A Screenful of Sugar?
Jon Schommer, Professor
Applequist and Ball provided an important update to their 2004 data regarding the types of content presented in prescription drug product claim ads.Their reference to Frosch's work (balancing policy with evidence in the regulation of prescription drug advertising) is outstanding and helps frame this important issue. My work with collaborator Lewis Glinert (Dartmouth College) that focuses upon prescription drug advertising...
Show More

Applequist and Ball provided an important update to their 2004 data regarding the types of content presented in prescription drug product claim ads.Their reference to Frosch's work (balancing policy with evidence in the regulation of prescription drug advertising) is outstanding and helps frame this important issue. My work with collaborator Lewis Glinert (Dartmouth College) that focuses upon prescription drug advertising on web sites benefits greatly from the work published by Applequist and Ball. Continued work that evaluates the content, oversight, organization, and language of prescription drug advertising will help frame decisions in this domain.
Competing interests: I am co-author (with Lewis Glinert, Dartmouth College) for a book entitled "A Screenful of Sugar? Prescription Drug Websites Investigated."
Show Less

Competing Interests: None declared.
Published on: (16 May 2018)
Page navigation anchor for Time for Congress to act
Time for Congress to act
Dominick L. Frosch, Senior Scientist
Congratulations to Dr. Applequist and Dr. Ball on a well-done and timely study. As a scientist I am proud to see our 2007 methods replicated with a recent sample of ads. As someone interested in more sensible health policy, I am troubled though, sadly, not surprised. In another paper we published on this topic in 2010 we wrote "DTCA amounts to a large and expensive uncontrolled experiment in population health, which to...
Show More

Congratulations to Dr. Applequist and Dr. Ball on a well-done and timely study. As a scientist I am proud to see our 2007 methods replicated with a recent sample of ads. As someone interested in more sensible health policy, I am troubled though, sadly, not surprised. In another paper we published on this topic in 2010 we wrote "DTCA amounts to a large and expensive uncontrolled experiment in population health, which to date shows decidedly mixed effects." The findings by Applequist and Ball don't spur much optimism that this situation has improved. The lack of funding for research on DTCA is one impediment. Lack of access to relevant data is another. Surely, the industry must know much more about the effects of this $6 billion/annually experiment it is funding than the public does. It is time for Congress to ask more probing questions. These new data call for it.
Competing interests: None declared
Show Less

Competing Interests: None declared.